Treatment of advanced Hodgkin's disease with high dose melphalan and autologous bone marrow transplantation
Affiliations
- PMID: 2673463
Item in Clipboard
Treatment of advanced Hodgkin's disease with high dose melphalan and autologous bone marrow transplantation
Bone Marrow Transplant.
1989 Jul.
Abstract
Twenty patients with Hodgkin's disease which had relapsed at least once after chemotherapy, were treated with melphalan 140-220 mg/m2 i.v. followed by reinfusion of non-cryopreserved autologous bone marrow. Four patients (20%) remain alive and disease-free 28, 45, 52, and 96 months after treatment respectively. There were no treatment-related deaths. This appears to be the only reported series of patients treated with a single agent in this situation. The results are comparable to those achieved by multi-agent regimens with autologous or allogeneic bone marrow transplantation.
Similar articles
-
Salvage chemotherapy with mini-BEAM for relapsed or refractory Hodgkin's disease prior to autologous peripheral blood stem cell transplantation.Haematologica. 1999 Nov;84(11):1007-11. Haematologica. 1999. PMID: 10553161 Clinical Trial.
-
The role of high-dose therapy and autologous bone marrow reinfusion in the treatment of Hodgkin's disease.Hematol Oncol Clin North Am. 1989 Jun;3(2):319-30. Hematol Oncol Clin North Am. 1989. PMID: 2663830 Review.
-
High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease.Biol Blood Marrow Transplant. 1997 Nov;3(5):261-6. Biol Blood Marrow Transplant. 1997. PMID: 9450921
-
Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.Eur J Haematol. 2007 Feb;78(2):93-101. doi: 10.1111/j.1600-0609.2006.00796.x. Eur J Haematol. 2007. PMID: 17313557 Clinical Trial.
-
Intensive therapy and autotransplantation in Hodgkin's disease.Stem Cells. 1994 Sep;12(5):477-93. doi: 10.1002/stem.5530120504. Stem Cells. 1994. PMID: 7804123 Review.
Cited by
-
Etoposide and adriamycin containing combination chemotherapy (HOPE-Bleo) for relapsed Hodgkin's disease.Br J Cancer. 1990 Jun;61(6):919-23. doi: 10.1038/bjc.1990.206. Br J Cancer. 1990. PMID: 1695523 Free PMC article.
-
Autologous transplantation in poor risk Hodgkin's disease using high dose melphalan/etoposide conditioning with non-cryopreserved marrow rescue. The Newcastle and Northern Region Lymphoma Group.Br J Cancer. 1993 Feb;67(2):383-7. doi: 10.1038/bjc.1993.70. Br J Cancer. 1993. PMID: 8431371 Free PMC article. Clinical Trial.
-
ChlVPP combination chemotherapy for Hodgkin's disease: long-term results.Br J Cancer. 1990 Aug;62(2):279-85. doi: 10.1038/bjc.1990.278. Br J Cancer. 1990. PMID: 2386744 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical